Somatostatin — A Regulatory Peptide of Clinical Importance by Bethge, N. et al.
Bethge, Diel and Usadel: Somatostatin - a regulatory peptide of clinical importance 603
J. Gin. Chem. Clin. Biochem.
Vol. 20,1982, pp. 603-613
Somatostatin — A Regulatory Peptide of Clinical Importance
EyN. Bethge
Institut für Pathologie, Universitätsklinikum Steglitz, Freie Universität Berlin, WestGermany,
F. Diel and K. H. Usadel
Zentrum der Inneren Medizin der Universität Frankfurt/M, West Germany
(Received December 23,1981/May 17,1982)
In memoriam Professor Dr. E. Altenähr
Summary: Somatostatin was first discovered in the hypothalmus and has since been located in many parts of the
central and periphefal nervous System, äs well äs in the pancreas and the gastrointestinal tract. Its main biological
activity is to inhibit the action of somatotropin (growth hormone, STH, GH) and a number of other hormones. The
therapeutic value of somatostatin has been demonstrated in the treatment of both acute bleeding gastric ulcers and
acute pancreatitis. In additioii, the measurement of somatostatin in the blood is a useful method for the screening of
somatostatin-produeing tumours. This paper reviews the location, action, clinical significance and measurement of
somatostatin.
Somatostatin - Ein Regulatorpeptid mit klinischer Bedeutung
Zusammenfassung: Somatostatin, zuerst im Hypothalamus entdeckt, ist in vielen Teilen des zentralen und peripheren
Nervensystems, im Pankreas und im Gästrointestinaltrakt lokalisiert. Seine biologische Hauptwirkung ist die Hem-
mung von Somatotropin (GH, STH) und einer Vielzahl anderer Hormone. Der therapeutische Wert von Somatostatin
konnte bei der Behandlung von akuten Magenulkusblutungen und akuter Pankreatitis gezeigt werden. Die Somatosta-
tin-Bestimmuiig im Blut stellt eine wertvolle Methode bei der Suche nach einem somatostatinproduzierenden Tumor
dar. Die Lokalisation, Wirkung, klinische Bedeutung und Bestimmung von Somatostatin wird dargestellt.
Introduction „ „ , . , „,, . „ . , . ,
of the hypothalamus. The capillanes of the capillary
Intensive reseärch has been carried out to identify the plexüs in this region are fenestrated and therefore
hormones of the hypothalamus which influence pitüitary , permeable to relatively large molecules. The long portal
function. So far, three hypothalamic hormones häve been veiiis of the hypothälamicJiypophyseal portal system
idontified and their biological effects in änimals and man drain the capillary plexüs into the sinusoids of the
investigated: thyrölib^riii (thyrotropin-releasing hör- ädenohypophysis. By this pathway, the h5 othalamic
mone, TRH), identified in 1969 by Guiltemin (1) and hormones control ädenohypophysis hormone secretion
Schally (2); Luliberin (luteinizing-hormone-releasing (fig. 2). Certain of these hormones affect more than
hormone, LHRH), isolated in 1971 by Schally (3); and one pitüitary hormone: e.g., thyroliberin causes the
somatostatin, reported by Guillemiii in 1973 (4) and by release of thyrotropin (thyrotropic hormone, TSH)
Schally in 1976 (5). Figure l shows the chemical struc- (l, 2) and prolactin (6); luliberin releases lutropin
tures of these three hormones. (luteinizing hormone, LH) and follitropin (follicle-
The tuberohypophyseal neurons are believed to syn- stimulating hormone, FSH) (3,7), and somatostatin
thesize, transport, and release the hypothalamic hör- inhibits the secretion of somatotropin (4) and thyro-
mones into perivascular spaces in the median eminence tropin (8).
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Fig. 2. Diagram of the hypothalamic-pituitary axis in coronal
section.
Left: The hypothalamicnieurohypophyseal System.
Supraoptic and paraventricular axons teiminate on
blood vessels in the posterior pituitary (neurohypo-
physis).
Right: The hypothalamic-adenohypophyseal System.
Tuberoinfundibular'neurqns, believed to be the source
of the hypothalamic regulatory hormones, terminate on
the capillary plexus in the median eminence. The pituitary
portal System is derived from branches of the internal
carotid, which forms a primary eapillary bed in the median
eminence. The long portal veins drain the capillary plexus
into the sinusoids of the anteriör pituitary (adenohypo-
physis). Supraoptic, paraventricular, and tuberoinfundi-
bular neurons are all classed äs neurosecretory cells. The
activity of tuberoinfundibular neurons is influenced by
monoaminergic cells. OT = qptie tract. (From Martin, J.
B. (1977) Clinical Neuroendocrinology, F. A. Davis
Company, Philadelphia, p. 13, with permission).
Localization of Somatostatin
Tissue locälization of Somatostatin has been elucidated
mainly by immunohistochemistry and by radioimmuno*
assay. For this reaspn, the term "spmatostatin-like
immunoreactivity" may be more äpprppriate |n this
context than "Somatostatin".
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Somatostatin, which was first discovered in the hypo-
thalamus is now known to be widely distributed through-











* Defined by Isolation and amino acid composition; all other
data are evaluated by immunological techniques.
Acetylcholine (208)
Contractions
Fig. 3. Multiple locations of Somatostatin and multiple effects of
Somatostatin. (From Guülemin, R. (1978) Science 202,
p. 397, (C) The Nobel Foundation 1978, with permission).
The hormone has also been detected in pancreatic islet
cells (Luft et al. 1974) (9) and in the so-called D-cells
qf the stomaeh and gut (10-16). Thyroliberin is
another peptide which is normally associated with the
brain, but which has also been found in the pancreas
and in the gastrointestinal tract (17). Conversely, many
gastrointestinal peptides such äs substance P (18,19),
vasoactive intestinal peptide (VIP) (20,21), neurotensin
(22), gastrin (23) and insulin 24) have been isolated
from brain tissue.
However, Somatostatin is not restricted to brain and gut.
Its presence has been demonstrated in the thyroid,
blood, cerebrospinal fluid, amniotic fluid, retina and
tumours of the pancreas and gut (see tab. l; fig. 3).
Intracellularly, Somatostatin has been identified in the
Golgi complex (25,26).
The disseminative distribution of Somatostatin suggests
a mainly paracrine function for the peptide, i.e. somato-
statin acts on neighbouring cells and tissues rather than
on some distant target receptors through dissemination
of its Signal by the bloodstream (27).
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Biosynthesis of Somatostatin
After the discovery of the existence of prohormones äs
biosynthetic precursors (e.g.: insulin, glucagon, gastrin,
cholecystokinin, parathyrin, 0-melanotropin and j3-en-
dorphin) (see I.e. (28) for review), the acceptance of
the formation of a series of peptide hormones from a
single precursor by post-translational cleavage has by
now become commonplace (29—32). In view of this
and the fact that many reports of the occurrence of
Somatostatin are based on immunological evidence, it is
hardly surprising that there is some conflict äs to the
exact nature of the peptide, but that there is some
consensus on its biosynthesis in the pancreas and
hypothalamus. The primary structure of a big-so-
matostatin was first described in 1980 byPradayrol et
al. (15). The big-somatostatin from porcine intestine is
an octacosapeptide, the so-called "somatostatin-28",
and its region 15—28 represents the previously known
tetradecapeptide Somatostatin (somatostatin-14). Big-
somatostatins from both pig and sheep hypothalamus
were found to have identical structures (33, 34).
Another big-somatostatin, a pentacosapeptide (somato-
statin-25) was found by Bohlen et al. 1980 (33). this
may be a further intermediate of the pathway to the
matured somatostatin-14. The N-terminal extension in
big-somatostatin is linked to the tetradecapeptide through
an Arg-Lys peptide bond, which is the characteristic
bond susceptible to cleavage by trypsin-like enzymes.
Both somatostatin-28 and somatostatin-14 are released
from the median eminence synaptosomes (35), and it
has been shown that subcellular fractions of the hypo-
thalamus can convert somatostatin-28 to somatostatin-14
(36).
Recent evidence from three independent groups has
demonstrated the existence of mRNA coding for a
precursor of Somatostatin in angler fish pancreas (37—
40). Moreover, the complete amino acid sequence of
this preprosomatostatin has been deduced from se-
quence analyses of cloned cDNA (37, 39). This pre-
cursor contains a Signal peptide which may be released
during the transit into the endoplasmic reticulum. The
resultant pancreatic prosomatostatin would be approxi-
mately 97 amino acid residues with MT = 10600 and
has the somatostatin-28 at the COOH-terminus (37).
In hypothalamic extracts, a 15000 Mr precursor of the
tetradecapeptide Somatostatin has been characterized
(41, 42). In addition, a hypothalamic extract containing
protease(s) capable of selectively converting this
15000 precursor into somatostatin-14 has also been
described (43).
In conclusion, to date, there is no clear evidence that
somatostatin-14 is formed from somatostatin-28 and
not from another intermediate within the event of
posttranslational modification.
Catabolism of Somatostatin
Specific proteolytic enzymes have been described for
the degradation of other regulatory peptides such äs
luliberin and thyroliberin (44—46). In the brain, somato^
statin may be cleaved by an indigenous neutral endo-
peptidase (cathepsin M) with speciilcity for Trp-8/Lys-9
(47). Experiments on Somatostatin analogues have
shown that the amino acid sequence from 7—10 is
important for biological activity (48). It is therefore
possible that the cleavage of Somatostatin by cathepsin-M
is of real catabolic significance. Intravenous injection of
Somatostatin is followed by a rapid disappearance of the
peptide from the blood. The half-life öf Somatostatin in
man has been calculated to be 1.7 min by radioimmüno-
assay and 1.9 min by radioreceptorassay (49, 50) äs
compared to the 1.1 min Md 3.3 min, respectively,
repprted by Sheppardet al. (51). In the rat, the half
life of somatostatin-28 is significantly longer thän that
of somatostatin44 (52). The mechaiiisms iiivolved in
this rapid disappearance from the blöodstream are not
clear. The most likely sites for elimination and excre-
tion of hypothalamic hormones are:
— elimination by circulating peptidases,
— distribution and binding to receptor sites in various
tissue beds,
— elimination by the liver and kidneys.
It has been shown by McMartin & Purdon (53) that a
plasma aminopeptidase can convert Somatostatin to a
biologically active peptide (des-Ala-l)-somatostatin. In a
recent report, the disappearance of tritiated Somato-
statin from the blood of rats after intravenous injection
was demonstrated by the uptake of 70% of the label in
the large peripheral tissues such äs muscle, skin and
intestine (54). In the same report, it was stated that less
than 10% of the injected label was recovered from the
liver and kidneys of the rats. More experiments will be
required before the true role of enzymic degradation in




Before the numerous effects of Somatostatin are de-
scribed, two questions have to be raised:
(a) what is the biologically active form of Somatostatin,
and
(b) what is known about the receptor sites öf somato-
statin in the tissue and its üitiacellular effects?
If somatpstatin^28 is an intermediate of the mature
somatostatin-14, the big-somatöstätin should haVe less
biological activity than somatostatin-14. Sbmatostatin=28,
however, shows equipotency with somatostatin-14 in
the Inhibition of somatotropin änd^röläcthi on a molar
J. Ciin. Chem. Clin. Biochem. / Vol. 20,1982 / No. 9
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basis in vitro (SS). On a molar basis, somatostatin-28 has
been found to be twice äs active äs somatostatin-14 in
inhibiting plasma glucagon and 10 times more active in
inhibiting plasma Insulin in the pancreas (SS).
Other comparative studies support these results and also
report somatostatin-28 to be a more potent inhibitor of
somatotropin in man (56, 57).
These differences in the inhibitory power of the two
peptides suggest that somatostatin-28 is not only a
presumable intermediate of somatostatin-14. A factor
contributing in pärt to the more potent biological
activity of somatostatin-28 could be the longer half
life of the larger peptide (52).
Mode of action
Investigations on the somatostatin receptors in rat
pituitary tumour cell membrane were first performed
by Schonbrunn and Tashjian Jr. (58). They described
receptor sites for somatostatin and found that pnly
those cell strains which had somatostatin receptors
could respond to the hormone. In addition, the number
of somatostatin receptors was modulated by thyro-
liberin (59). From other hormones» for example,
insulin, it is known that the number of receptor sites
in a cell is regulated by the hormone itself (60). Binding
of somatostatin to pituitary plasma membrane has also
been reported (61). Recently, Srikant &Patel demon-
strated that there are different receptors for somato-
statin-28 and somatostatin-14 in the normal rat pituitary
and cerebral cortex (62,63). In comparison to somato-
statin-14, somatostatin-28 shows a higher affinity fof
pituitary receptors than for cerebral cortex receptors.
A" specific somatostatin binding factor in the cytosol of
the dark islets cell area of the chicken pancreas has beeil
detiionstrated (643 65). Another group (66) found a
somatostatin binding protein while investigating a number
of tissues (mainly from the rat). In both species, spe-
cificity of binding was demonstrated. However, differ-
ences in the data reported suggest differences in the
näture of the somatostatin binding. Secretion vesicles
isolated from pancreas islet cells have also been shown
to exhibit somatostatin binding (67).
It therefore appears that there are specific binding sites
in the somatostatin target tissue^ but its exact nature
and role in the Initiation of the biological response are
still unclear. Inhibition generated by somatostatin is
accoinpanied by an intracellular decrease in cyclic
AMP levels (68,69) and an increäse of cyclic GMP,
respectively (70), Moreover, somatostatin specifically
inhibits the cyclic AMP-dependent protein kinase
activity of secretion vesicles isolated from pancreatic
islets and the anterior pituitary (71).
Pituitary hormones
Somatostatin inhibits the secretion of somatotropin in
animals and in man after virtually all known physiologi-
cal and pharmacological Stimuli, e.g., arginine (72),
L-dopa (72), insulin-induced hypoglycaemia (73, 74),
sleep in normal subjects (75) and in patients with
somatotropin-producing pituitary tumours äs in
acrpmegaly (74, 76). Stimulation of thyrotropin by
thyroliberin can be abolished by somatostatin (8).
There is no effect on the thyroliberin-induced prolactin
secretion in vivo, but an Inhibition of prolactin secre-
tion in vitro has been achieved (77). Under pathological
conditions, somatostatin lowers prolactin levels in
patients with acromegaly, but not in normal subjects
(78).
However, these results were not supported by other
authors (74). In man, normal corticotropin levels are
not influenced by somatostatin (74,79), but the
elevated corticotropin levels in patients with Cushing's
disease otNelson's disease are lowered by somatostatin
infusion (80—82). Lutropin and follitropin show no
response to somatostatin (79).
Endocrine pancreas
In l973,Alberti et al. (83) reported that plasma insulin
levels were decreased after somatostatin infusion.'The
säme effect on glucagon has also been described (84, 85).
In normal man, infusioii of somatostatin lowers plasma
glucose levels. This fact indicates the important physio-
logicäl role of glucagon in glucose homeostasis (86). The
pancreatic polypeptide produced by the F-cells (87) in
the pancreatic islets is also suppressed by somatostatin
(88). Figure 4 summarizes the influence of somatostatin
on glucose homeostatis.
Exocrine pancreas and gastrointestinal tract
Somatostatin has a strong effect on various gastrointesti-
nal hormones and the function of the digestive System.
For example, somatostatin inhibits the releäse of gastrin
(89,90), pepsifi secretion (91), cholecystokinin-pancreo-
zymin (92), secretin (93), motilin (94) and VIP (vaso-
äctive intestinal peptide) in VIP-producing tumours (95).
Conversely, experiments on isolated perfused pancreas
have shown that somatostatin releäse is stimulated by
gastrointestinal peptides like GIP (gastric inhibitory
peptide), VIP, glucagon, glucose and arginine (96—99).
Somatostatin may also reduce duodenal motility (100),
gall bladder contractions (92) and gastric emptying (93).
Splanchnic blood flow is surprisingly reduced during
continuous intravenous somatostatin infusion in man
and animals (101-104).
Adrenal gland
It has been reported that somatostatin inhibits renin-
antiotensin-aldosterone adrenal cortex Stimulation in
vivo (105—107). Since glomerulosa cells from the adrenal
cortex seem to be responsible for aldosterone produc-
tion (108), cells were isolated from the bovine adrenal
cortex, and in vitro Stimulation by corticotropin and the
J. Clin. Chem. Clin, Biochem. / Vol. 20,1982 / No. 9
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Fig. 4. Regulation of glucose homeostasis. Somatostatin may be involved in the glucose homeostatis during meals.
influence of added Somatostatin were measured by
aldosterone determination (109). The results indicated
that the inhibitory effect of Somatostatin cannot be
evaluated in the bovine aldosterone-producing System
in vitro.
Other effects of Somatostatin
The concept that Somatostatin is a general inhibitory
hormone (l 10) cannot be applied to its effect on mast
cells. Here, Somatostatin causes a histamine release in
vitro (l 14). Furthermore, in vivo studies have shown
that Somatostatin enforces the passive cutaneous
anaphylaxis in sensitized rats at doses greater than
1 1/1(115).
Usadel and collaborators found that Somatostatin treat-
ment led to an increase in the survival rate in phalloidin-
intoxicated rats (l 16), and Szabo & Usadel have postu-
lated that this cytoprotective effect is caused via a
systemic organoproteetipn (117) and vasculöprotectiqri
(118). The beneficial effect of Somatostatin was also
seen in experimental adrenal and lurig injuries (l 19) äs
well äs in various shock syndromes '(120). The mode of
these actions needs further investigation.
Clinical Importance
Influence in pathogenesis
After discovering the inhibitory effect of Somatostatin
on glucose and insulin, clinical1 studies were performed
in order to evaluate the importance of this peptide in
diabetes mellitus. Somatostatin lowers blopd glucose
levels in patients with diabetes mellitus and in normal
subjects (121—123). Via the artificial pancreas somato-
statin is able to reduce the requirement of insulin in
more than 70% öf patients with juvenüe diabetes (124).
Pfeiffer commented in a recent reviq\v that a selective
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Das Kurzlehrbuch für Zahnärzte und
Studierende behandelt die Biochemie
der Zähne, des Zahnhalteapparates und
der Mundhöhle, Es werden Chemie und
Stoffwechsel der organischen Matrix der
Zahnhartsubstanz, Biomineralisation,
Fluoridstoffwechsel und die spezielle
Bipchemie des Speichels und der
Mikroorganismen der Mundhöhle
beschrieben. Sie bilden die Grundlage
für die Pathobiochemie der beiden
häufigsten Erkrankungen der
Odpntologie - der Karies und der
Parodontopathie. Die Darstellung umfaßt
neben pathogenetisohen auch
präventive Aspekte der Karies Und
Parodontopathie sowie eine Übersicht
über die chemische Zusammensetzung
und Wirkungsweise von Zahnpflege-
mitteln.
Der behandelte Inhalt des Buches
berücksichtigt auch die Prüfungsordnung
für Zahnärzte,
Aus dem Inhalt (Häuptkapitel):
Zahnmedizin und Biochemie · Chemie
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analogue, without the general inhibiting potency of
somatostatin, could play a role in diabetes treatment
(125). There is also some indication that the hormone
may be involved in the pathogenesis of diabetes mellitus.
In the pancreatic islets of both patients with juvenile
diabetes and in rats with diabetes induced by strepto-
zotocin, a hypertrophy and hyperplasia of D-cells con-
taining somatostatin has been found (126). Elevated
somatostatin and glucagon release were observed in iso-
lated pancreatic islets from streptozotocin diabetic rats
(127-129). D-cell hyperplasia in diabetes could be
interpreted s an ineffective attempt to prevent the
glucagon hypersecretion by elevated local somatostatin
production (126). In the gastrointestinal tract, somato-
statin inhibits gastrin secretion (89). The somatostatin-
producing D-cells are located in close proximity to the
gastrin-producing G-cells (127). In patients with duo-
denal ulcers, a decrease in D-cell numbers of up to 70%
has been found in the mucosa (128,129).
A short time after the discovery of somatostatin, its
effect on patients suffering from acromegaly was tested.
Several groups reported a dose-dependent fall in the
plasma level of somatotropin (74,76,78). However,
after stopping somatostatin infusion, elevated somato-
tropin levels returned.
Somatostatinoma
The pancreas has a great potential for tumour formation.
Most tumours are derived from the exocrine pancreas.
However, an increasing number from the endocrine
pancreas have been identified in the past 25 years.
Recently, somatostatin-producing tumours, somato-
statinomas, have been found in the pancreas (ISO-
IS?), duodenum (138), and jejunum (139). Ectopic
productiori of somatostatin by a cultured human pul-
monary small cell carcinoma has also been observed
(140). Endocrine and exocrine pancreatic insufficiency,
steatorrhea, diabetes mellitus, and cholelithiasis in the
presence of a duodenal tumour suggest sbmato-
statinpma (134). Elevated plasma somatostatin and
immunohistochemical examination of the tumour tissue
can confirm the somatostatinoma diagnosis.
Clinical Somatostatin Treatment
Using experimental uleer models (141 ,-142), somato-
statin was shown to be effective, s the permanent infu-
sion of somatostatin in patients suffering from bleeding
gastric lcers stopped bleeding within 6 to 8 hours (143,
144).
A randomized controlled trial showed somatostatin to
be m re effective than cimetid ne in stopping the
bleeding from a peptic ulcer (145).
Acute pancreatitis is also a conceivable candidate for
somatostatin treatment. In experimentally induced
haemorrhagic pancreatitis in dogs, somatostatin caused
a remarkable reduction in the clinical Symptoms (146).
Prophylactic infusion of somatostatin before the Start of
an Operation on the pancreas reduced the postoperative
complications (147). Also, two studies have shown an
impressive recovery from acute pancreatitis after treat-
ment with somatostatin (148,149). For further investiga-
tion on somatostatin treatment in acute pancreatitis, a
multicentre double-blind trial was started in 1980. The
results will be reported in 1982 (150).
Detection of Somatostatin
If a clinician is presented with a tumour which produces
neither insulin, gastrin, nor glucagon, it is recommended
by the German Endocrine Society that the plasma levels
of somatostatin be measured (151).
Several radioligand binding assays for somatostatin
measurement have been described (49, 50,152-162).
Normal somatostatin plasma levels in man are in the
r nge of 40 ng/1 (50). With immunohistochemical
methods, e.g., peroxidase-antiperoxidase technique
(163, 164), somatostatin can be detected in the tissue.
The distribution of somatostatin in the pancreatic islet
is shown in figure 5.
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Fig. 5. Numerous somatostatin cells (D-cells) are present in the
islet of Langerhans. Human pancreas section incubated
with antisomatostatin serum (153). Sites of antibody
attachment visualized with diaminobenzidine usually
appear dark (peroxidase-anti-peroxidase technique,
Bethge (164). Magnification: 260X.
Conclusion
Somatostatin is involved in the regulation of somato-
tropin secretion in the pituitary and may play a funda-
mental role in glucose homeostatis and assimilation of
nutrients. At the present time, little is known about the
ac on of somatostatin in the central nervous System
(165).
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The peptide has a beneficial effect in a variety of ill-
nesses, in particular, bleeding gastric ulcers and various
experimental organ lesions, e.g., liver, lung, adrenal and
shock syndromes.
It is likely that the numerous regulatory effects of the
peptide will only be properly integrated and understood
when the events occurring in the cell after the ligand-
receptor interaction are better known at a molecular
level.
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